Literature DB >> 6135437

Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

P J Barnes, N B Pride.   

Abstract

We have compared bronchodilator dose-response curves to inhaled salbutamol in seven normal and eight asthmatic subjects. In all normal subjects maximal bronchodilatation measured by partial flow volume curves was achieved at a cumulative dose of 110 micrograms. The dose necessary to produce half maximal response (ED50) was 23 +/- 2 micrograms (mean +/- s.e. mean) with a range of 18-28 micrograms. In asthmatic subjects maximal bronchodilatation measured by FEV1 and by maximal flow volume curves was achieved at significantly higher (P less than 0.01) doses of salbutamol with a mean ED50 of 83 +/- 28 micrograms and range of 25-251 micrograms. There was a significant (P less than 0.05) correlation between ED50 and % predicted baseline FEV1. This is more likely to reflect impaired access of drug for airway beta-adrenoceptors than impaired beta-adrenoceptor function in asthma. In five asthmatic subjects dose-response curves to salbutamol and isoprenaline were compared and found to be similar, thus providing no evidence that salbutamol is a partial agonist in vivo, as it appears to be in vitro.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135437      PMCID: PMC1427940          DOI: 10.1111/j.1365-2125.1983.tb01549.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Aerosol penetrance: a sensitive index of peripheral airways obstruction.

Authors:  M B Dolovich; J Sanchis; C Rossman; M T Newhouse
Journal:  J Appl Physiol       Date:  1976-03       Impact factor: 3.531

2.  Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.

Authors:  H S Nelson; D Raine; H C Doner; W C Posey
Journal:  Am Rev Respir Dis       Date:  1977-11

3.  Comparison of cardiorespiratory effects of isoprenaline and salbutamol in patients with bronchial asthma.

Authors:  D A Warrell; D G Robertson; J N Howes; M E Conolly; J W Paterson; L J Beilin; C T Dollery
Journal:  Br Med J       Date:  1970-01-10

4.  Pharmacokinetics of inhaled substances.

Authors:  D S Davies
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

5.  beta-adrenergic agonist resistance in normal human airways.

Authors:  S T Holgate; C J Baldwin; A E Tattersfield
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

6.  Leukocyte cyclic adenosine monophosphate in asthmatic children. Effects of adrenergic therapy.

Authors:  H G Morris; S A Rusnak; K Barzens
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

7.  The beta-adrenoceptor of the human lymphocyte and human lung parenchyma.

Authors:  M E Conolly; J K Greenacre
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

8.  Development of "resistance" in beta-adrenergic receptors of asthmatic patients.

Authors:  N L Svedmyr; S A Larsson; G K Thiringer
Journal:  Chest       Date:  1976-04       Impact factor: 9.410

9.  Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation.

Authors:  J W Jenne; T W Chick; R D Strickland; F J Wall
Journal:  J Allergy Clin Immunol       Date:  1977-05       Impact factor: 10.793

10.  The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function.

Authors:  M E Conolly; J K Greenacre
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

View more
  23 in total

Review 1.  Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?

Authors:  S P Newman
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

2.  Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard?

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

3.  Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.

Authors:  R L Lalonde; D Ouellet; E K Kimanani; D Potvin; L M Vaughan; M R Hill
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

4.  Is xamoterol safe in chronic airflow obstruction?

Authors:  J A Roberts; V F Challenor; D G Waller
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  A method for bioassay of potency and effectiveness of inhaled bronchodilators in normal subjects.

Authors:  R W Foster; G K Atanga; J R Carpenter; D E Evans; K Rakshi; R C Small
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

6.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.

Authors:  Heather S Tomlinson; Sarah A Corlett; Martin B Allen; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 8.  Airway receptors.

Authors:  P J Barnes
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

9.  Pharmacological bronchodilation is partially mediated by reduced airway wall stiffness.

Authors:  T K Ansell; P B Noble; H W Mitchell; P K McFawn
Journal:  Br J Pharmacol       Date:  2014-10       Impact factor: 8.739

10.  Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding.

Authors:  H Lemoine; C Overlack; A Köhl; H Worth; D Reinhardt
Journal:  Lung       Date:  1992       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.